Table 2
Alerts, Number of Respondents Agreeing to Turn Off the Alert, and Reason Most Often Mentioned
| Number of Clinicians Agreeing to Turn Off Alerts | ||||||||||
| DDI Database Code | DDI Name | Seriousness Index | Evidence Index | Number of Alert Overrides in 1 Month | Int (n = 6) | Card (n = 6) | Surg (n = 6) | Pharm (n = 6) | Total (n = 24) | Reason Most Often Mentioned |
| 1066 | Potassium and potassium-saving diuretics | F | 3 | 41 | 4 | 1 | 0 | 6 | 11 (46%) | Knowledge (7) |
| 0035 | ACE inhibitors and potassium-saving diuretics | F | 2 | 112 | 1 | 2 | 0 | 6 | 9 (38%) | Knowledge (10) |
| 0280 | Beta-blockers and verapamil/diltiazem | E | 3 | 12 | 1 | 2 | 1 | 3 | 7 (29%) | Knowledge (6) Intentional (6) |
| 5096 | QT interval prolonging drugs erythromycin/clarithromycin/voriconazole | E | 3 | 10 | 1 | 0 | 0 | 0 | 1 (4%) | Seriousness (11) |
| 3395 | Statins (simvastatin/atorvastatin) and verapamil/diltiazem | E | 3 | 10 | 0 | 1 | 0 | 0 | 1 (4%) | Text (9) |
| 5088 | QT interval prolonging drugs and QT interval prolonging drugs (except erythromycin, clarithromycin, voriconazole) | E | 1 | 154 | 0 | 0 | 0 | 0 | 0 (0%) | Seriousness (12) |
| 0531 | Coumarins and amiodarone/propafenone | D | 3 | 47 | 3 | 4 | 0 | 5 | 12 (50%) | Monitoring (12) |
| 0299 | Nonselective beta-blockers and insulin | D | 3 | 18 | 3 | 4 | 0 | 4 | 11 (46%) | Knowledge (7) |
| 0019 | ACE inhibitors and diuretics | D | 3 | 312 | 2 | 2 | 0 | 3 | 7 (29%) | Knowledge (6) Intentional (6) |
| 3921 | Haloperidol and enzyme inductors | D | 3 | 14 | 1 | 0 | 1 | 3 | 5 (21%) | Knowledge (7) |
| 1155 | Diuretics and NSAIDs | D | 3 | 41 | 2 | 0 | 0 | 2 | 4 (17%) | Seriousness (14) |
| 0027 | ACE inhibitors and NSAIDs | D | 3 | 30 | 1 | 0 | 0 | 2 | 3 (13%) | Seriousness (14) |
| 0124 | Digoxin and amiodarone | D | 3 | 16 | 0 | 1 | 0 | 1 | 2 (8%) | Seriousness (9) Knowledge (9) |
| 1465 | Tacrolimus and enzyme inhibitors | D | 3 | 27 | 0 | 0 | 0 | 0 | 0 (0%) | Seriousness (11) |
| 3360 | NSAIDs (except COX-2 inhibitors) and selective 5HT reuptake inhibitors/trazodone | C | 4 | 15 | 0 | 0 | 1 | 1 | 2 (8%) | Knowledge (9) |
| 0272 | Beta-blockers and NSAIDs | C | 3 | 37 | 5 | 3 | 0 | 4 | 12 (50%) | Knowledge (9) |
| 2046 | NSAIDs (except COX-2 inhibitors) and corticosteroids | C | 3 | 83 | 2 | 1 | 1 | 2 | 6 (25%) | Knowledge (9) |
| 0736 | Coumarins and NSAIDs | C | 3 | 29 | 2 | 1 | 0 | 2 | 5 (21%) | Knowledge (6) |
| 0310 | Nonselective beta-blockers and beta-adrenergic agonists | C | 3 | 12 | 2 | 2 | 0 | 1 | 5 (21%) | Text (8) |
| 0302 | Selective beta-blockers and insulin | B | 3 | 160 | 3 | 4 | 0 | 6 | 13 (54%) | Knowledge (9) |
| 3964 | Beta-blockers and oral hypoglycemic drugs | B | 3 | 57 | 3 | 3 | 1 | 4 | 11 (46%) | Knowledge (8) |
| 1228 | AT receptor antagonists and diuretics | B | 3 | 87 | 2 | 3 | 0 | 3 | 8 (33%) | Knowledge (5) Intentional (5) |
| 0078 | Alpha-blocking drugs (for benign prostate hyperplasia) and beta-blockers/calcium channel blockers | B | 3 | 78 | 1 | 0 | 0 | 4 | 5 (21%) | Knowledge (8) |
| 0345 | Calcium channel blockers and CYP3A4 inhibitors | B | 3 | 11 | 3 | 0 | 0 | 2 | 5 (21%) | Knowledge (10) |
| Total | 1,413 | 42 | 34 | 5 | 64 | 145 | ||||
-
The DDIs are ordered according to the seriousness index. () = number of respondents mentioning this reason.
-
5HT = serotonin; ACE = angiotensin-converting enzyme; AT = angiotensin; Card = cardiology; COX-2 = cyclooxygenase-2; CYP3A4 = cytochrome P450 3A4; DDI = drug–drug interaction; Int = internal medicine; NSAID = nonsteroidal anti-inflammatory drug; Pharm = hospital pharmacy; Surg = surgery.
